Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With


July 31, 2017 (STL.News) This marks another milestone for this collaboration and is a meaningful step forward on the path to bringing a novel and first-in-class therapy to patients with type 1 diabetes. This decision allows us to play a significant role in the commercialization of sotagliflozin, if the medicine is approved by the FDA, [ ] The post Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With appeared first on STL News.
http://bit.ly/2ue1IRm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s